Results 111 to 120 of about 33,038 (222)
The Prostate, Volume 86, Issue 11, Page 1187-1194, August 2026.ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala +11 more
wiley +1 more source
The Prostate, Volume 86, Issue 11, Page 1233-1240, August 2026.ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma +18 more
wiley +1 more source
Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.ABSTRACT Eukaryotic translation initiation factor 3 subunit F (eIF3f) is a critical component of the eIF3 complex and plays a pivotal role in diverse biological processes, including cell proliferation, apoptosis, adhesion, and transcriptional regulation.
Yujinpeng Hao +3 more
wiley +1 more source
Isothiocyanates as Ferroptosis Inducers to Promote Cancer Cell Death
Phytotherapy Research, Volume 40, Issue 8, Page 5119-5131, August 2026.ABSTRACT Cancer remains a leading cause of global mortality, with the therapeutic efficacy of anticancer drugs often hampered by late diagnosis and the development of chemotherapy resistance. Ferroptosis is an iron‐dependent form of regulated non‐apoptotic cell death driven by lipid peroxidation.
Valentina Citi +6 more
wiley +1 more source
Journal of Medical Imaging and Radiation Oncology, Volume 70, Issue 5, Page 407-413, August 2026.ABSTRACT Introduction 68Ga prostate‐specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake.
Geoffrey Liu, Shane Lee, Kabir Ahmad
wiley +1 more source
Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 546-556, August 2026.Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong +28 more
wiley +1 more source
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Cancer Management and Research, 2015 Rosa Greasley,1 Mohammad Khabazhaitajer,1 Derek J Rosario2 1The Department of Oncology, The University of Sheffield, Sheffield, UK; 2The Department of Urology, Sheffield Teaching Hospitals, The Royal Hallamshire Hospital, Sheffield, UK Abstract: Recent ...
Greasley R, Khabazhaitajer M, Rosario DJ
doaj
Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience
BJU International, Volume 138, Issue 2, Page 297-305, August 2026.Objectives To report long‐term oncological outcomes of men with intermediate‐risk prostate cancer managed with active surveillance at a single centre. Subjects/Patients and Methods We retrospectively analysed a prospectively maintained Manitoba Prostate Centre active surveillance database.
Steven Lu +3 more
wiley +1 more source
Cancer Science, Volume 117, Issue 8, Page 2166-2180, August 2026.Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang +8 more
wiley +1 more source
Histopathology, Volume 89, Issue 2, Page 240-250, August 2026.FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao +11 more
wiley +1 more source